Zenas BioPharma, Inc. (ZBIO)
| Market Cap | 382.05M |
| Revenue (ttm) | 5.00M |
| Net Income (ttm) | -156.99M |
| Shares Out | 41.80M |
| EPS (ttm) | -11.89 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 389,465 |
| Open | 9.39 |
| Previous Close | 9.31 |
| Day's Range | 8.87 - 9.79 |
| 52-Week Range | 5.83 - 26.25 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 32.29 (+253.28%) |
| Earnings Date | May 16, 2025 |
About ZBIO
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFα monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an ... [Read more]
Financial Performance
In 2024, Zenas BioPharma's revenue was $5.00 million, a decrease of -90.00% compared to the previous year's $50.00 million. Losses were -$156.99 million, 322.9% more than in 2023.
Financial numbers in USD Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for ZBIO stock is "Strong Buy." The 12-month stock price forecast is $32.29, which is an increase of 253.28% from the latest price.
News
Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress
On Thursday, Wedbush initiated coverage on Zenas BioPharma, Inc. ZBIO, a clinical-stage global biopharmaceutical company focused on developing therapies for autoimmune disease.
Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer
–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies–
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
- Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in...
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference
WALTHAM, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the ...
Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
-Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company growth strategy-
Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
-INDIGO is the largest clinical trial conducted in patients living with IgG4-RD- -Topline INDIGO results expected by the end of 2025- WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma,...
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the d...
Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering
WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and ...
U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market
Six IPOs debuted this past week, including three deals of more than $100 million. Seven IPOs submitted initial filings. Outparcel REIT FrontView REIT filed to raise $100 million, and Chinese on-demand...
Zenas BioPharma Announces Pricing of Upsized Initial Public Offering
WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and ...
U.S. IPO Weekly Recap: 2 APAC Microcaps Go Public In Short Labor Day Week As The Pipeline Grows
Two small IPOs and two SPACs debuted this past week - Pheton Holdings, Powell Max, Vine Hill Capital, and Andretti Acquisition II, respectively. Eight IPOs submitted initial filings this past week, in...
Zenas BioPharma Seeks IPO For Inflammatory Treatment Trials
Zenas BioPharma has filed to raise $100 million in an IPO to advance its Phase 3 and Phase 2 trials for obexelimab, although the final figure may differ. The company is developing antibody-based treat...
U.S. IPO Weekly Recap: WeRide Delays Its IPO As Pipeline Gets A Boost
Two small IPOs debuted this past week, while six IPOs submitted initial filings. Six IPOs submitted initial filings this week, including four names which filed to raise $100 million or more. There are...
Immunology-focused biotech Zenas BioPharma files for an estimated $150 million IPO
Zenas BioPharma, a Phase 3 biotech developing therapies for autoimmune and inflammatory diseases, filed on Thursday with the SEC to raise up to $100 million in an initial public offering. However, thi...
Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO
Bristol-Myers Squibb-backed Zenas BioPharma has filed to go public in the United States, a regulatory filing showed on Thursday, underscoring improving investor appetite for new listings.
Zenas BioPharma IPO Registration Document (S-1)
Zenas BioPharma has filed to go public with an IPO on the NASDAQ.